Microsphere-Based Drug Delivery to Alveolar Macrophages - a Review doi.org/10.26538/tjnpr/v4i10.2
Main Article Content
Abstract
The lungs have a large surface area and high permeability, hence pulmonary delivery systems provide both local and systemic therapeutic effects. Pulmonary delivery system has been selected by many researchers because the route of administration is not invasive, has low metabolic activity, controlled environment for systemic absorption and avoids first pass metabolism. Alveolar macrophages are the first defense in the lung tissue to fight airborne pollutant, other foreign particle and pathogen by phagocytosis mechanism. Alveolar macrophages play an important role in the process of activation of the adaptive immunity including in inflammation and cancer diseases. Drug targeting to alveolar macrophages can achieve improvement in efficacy of therapeutic treatment for medical conditions including tumor, cancer, inflammation and infection. Respiratory infection-causing bacteria such as
tuberculosis and pneumonia are able to survive in alveolar macrophages and they turn macrophages become a reservoir. This presents the challenge of making macrophages as targets in pulmonary delivery system because most of drugs do not reach the macrophages level effectively. To achieve this goal, the use of carrier particles in either micro-sized or nano-sized technology is the right choice. This review focuses on the influences of various physicochemical properties of microspheres carrier include particle size, aerosolisation property, morphology surface charge, surface properties and hydrophilicity on their uptake by alveolar macrophages
either enhance macrophages uptake or decrease macrophages uptake. Making macrophage a target of treatment especially for infectious diseases is a promising strategy to improve the efficacy of treatment although in its development there are still many challenges.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Rashid J, Patel B, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). J Cont Rel. 2017; 250:96-106.
Jyoti K, Pandey RS, Kush P, Kaushik D, Jain UK, Madan J. Inhalable bioresponsive chitosan microspheres of doxorubicin and soluble curcumin augmented drug delivery in lung cancer cells. Int J Biol Macromol. 2017; 98:50-58.
Lin XF, Kankala RK, Tang N, Xu P‐Y, Hao, L‐Z, Yang D.‐ Y, Wang S‐B, Zhang YS, Chen AZ. Supercritical Fluid‐ Assisted Porous Microspheres for Efficient Delivery of Insulin and Inhalation Therapy of Diabetes. Adv. Healthcare Mater. 2019; 8:1800910.
She W, Mei Z, Zhao H, Li G, Lin Y. Nebulized inhalation of Anti Nerve Growth Factor Microspheres Inhibits Airway remodeling in an Ovalbumin-induced Rat Asthma Model. J Aerosol Pulm Drug Deliv. 2019; 32(2):70-77.
Yildiz-Pekoz A and Ozsoy Y. Inhaled Heparin: Therapeutic Efficacy And Recent Formulations. J Aerosol Med Pulm Drug Deliv. 2017; 30(3):143-156.
Parikh R, Dalwadi S, Aboti P, Patel L. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis. The J of Antibio. 2014; (67):387–394.
Klinkert K, Whelan D, Clover Aj, Leblond AL, Kumar AH, Caplice, NM. Selective M2 macrophage depletion leads to prolonged inflammation in surgical wounds. Eur Surg Res. 2017; 58:109-120.
Aldawsari HM, Gorain B, Alhakamy NA, Md S. Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression. J Drug Target. 2020; 28(2):166-175.
Zhang L, Wang Y, Wu G. Macrophages: friend or foe in idiopathic pulmonary fibrosis?. Respir Res. 2018; 19:170.
Swirski FK, Robins CS, Nahednrof M. Development and function of arterial and cardiac macrophages. Trends Immunol. 2016; 37:32-40.
Jayachandran R, Dasgupta SB, Pieters J. Surviving the macrophage: tools and tricks employed by Mycobacterium tuberculosis. Curr Top Microbiol Immunol. 2014; 374:189- 209.
Roopngam P, Liu K, Mei L, Zheng Y, Zhu X, Tsai HI, Huang L. Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response. Int J Nanomed. 2016; 11:5361–5370.
Loira-Pastoriza C, Todorof J, Vanveber R. Delivery Startegies for sustained drug release in the lung. Adv Drug Deliv Rev. 2014; 75:81-91.
Paranjpe M and Müller-Goymann CC. Nanoparticlemediated pulmonary drug delivery: a review. Int J Mol Sci. 2014; 8;15(4):5852-73.
Dhand C, Molamma PP, Oger W, Beuerman R, Lakshminarayanan, Neeraj D, Seeram R. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. Review. RSC Adv. 2014; 4:32673-32689.
Weiss G and Schaible UE. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. 2015; 264:182–203.
Mosaiab T, Farr DC, Keifel MJ, Houston TA. Carbohydrate-based nanocarriers and their application to target macrophages and deliver antimicrobial agent. Adv Drug Deliv Rev. 2019; (15):94-129.
Sprenger M, Kasper L, Hensel M, Hube B, Metabolic adaptation of intracellular bacteria and fungi to macrophages. Int J Med Microbiol. 018; 308(1):215-227.
Morales-Nebreda L, Misharin AV, Perlman H, Budinger GR. The heterogeneity of lung macrophages in the susceptibility to disease. Eur Resp Rev. 2015; 24:505–509.
Garapaty A and Champion JA. Tunable particles alter macrophage uptake based on combinatorial effects of physical properties. Bioengin & Trans Med, 2017:92-101.
Nimje N, Agarwal A, Saraogi GK, Lariya N, Rai G, Agrawal H, Agrawal GP. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target. 2009; 17:777–787.
Liu Y, Hardie J, Zhang X, Rotello VM. Effects of engineered nanoparticles on the innate immune system. Sem Immunol. 2017; 34:25-32.
Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv. 2010; 23:207-217.
El-Sherbiny IM, Villanueva DG, Herrera D, Smyth HD. Overcoming lung clearance mechanisms for controlled release drug delivery. Cont Pulm Drug Deliv. Springer. 2011. 101–126 p.
Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G, Makino K, Terada H. Delivery of rifampicinPLGA microspheres into alveolar macrophagesi is promising for treatment of tuberculosis. J Cont Rel. 2010; 142:339-346.
Costa A, Pinheiro M, Magalhães J. The formulation of nanomedicines for treating tuberculosis. Adv Drug Deliv Rev. 2016; 102:102-115.
Iversen TG, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today. 2011; 6(2):176- 185.
Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticle for pulmonary drug delivery. Biomater. 2009; 30(10): 1947- 1953.
Makino K, Nobuko Y, Kazue H, Nobuyuki H, Hiroyuki O, Hiroshi T. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Coll Surf B: Biointer. 2003; 27:33-39.
Hirota K, Taizo H, Hideyuki H, Fuminori I, Hiroyuki I, Chie K, Gen-Ichiro S, Kimiko M, Hiroshi Terada. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Cont Rel. 2007; 119:69–76.
Hwang SM, Kim DD, Chung SJ. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Cont Rel. 2008; 129:100-106.
Park JH, Hyo-Eon J, Dae-Duk K, Suk-Jae C, Won-Sik S, Chang-Koo S. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm. 2013; 441:562– 569.
Tiwari S, Chaturvedi AP, Tripathi YB, M Brameshwar. Microspheres based on mannosylated lysine-co-sodium alginate for macrophage-specific delivery of isoniazid. Carb Pol. 2012; 87(2):1575-1582.
Zhiqiang L, Xia L, Bingshui X, Cuimi D, Jiangxue L, Xuhui Z, Xiqin Y, Wenhao D, Heather J, Heqiu Z, Xiaoyan F. A novel and simple preparative method for uniform-sized PLGA microspheres: Preliminary application in antitubercular drug delivery. Coll Surf B: Biointer. 2016;145:679-687.
Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2012; 9:32-38.
Lakio S, Morton DAV, Ralph AP, Lambert P. Optimizing aerosolization of a high-dose L-arginine powder for pulmonary delivery. AJPS. 2015; 10(6):528-540.
Luinstra M, Grasmeijer F, Hagedoorn P, Moes JR, Frijlink HW, Boer AH. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur J Pharm Biopharm. 2015; 97:22–29.
Du P, Du J, Smyth HD. Evaluation of Granulated Lactose as a Carrier for DPI Formulations 1: Effect of Granule Size. AAPS. 2016; 15(6):1417–1428.
Takeuchi I, Yoshihiro T, Yuki T, Kazuhiro O, Kimiko M. Effects of L-leucine on PLGA microparticles for pulmonaryadministration prepared using spray drying: fine particle fraction and phagocytotic ratioof alveolar macrophages. Coll Surf A: Phys Eng Asp. 2018; 537:411-417.
David CJ, Patel RB, Mitchell JP. Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol. AAPS. 2017; 18:3296–3306.
Sharma D, Valenta DT, Altman Y, Harvey S, Xie H, Mitragotri S, Smith JW. Polymer Particle shape independently influences binding and internalization by macrophages. J Cont Rel. 2010; 147(3):408-412.
Chikaura H, Nakashima Y, Fujiwara Y, Komohara Y, Takeya M, Nakanishi Y. Effect of particle size on biological response by human monocyte-derived macrophages. Biosurf Biotri. 2016; 2(1):18-25.
Yoo JW and Mitragotri S. Polymer particles that switch shape in response to a stimulus. In Proc Natl Acad Sci. 2010; 107(25):1125-11210.
Pricer WE and Ashwell G. The binding of desialylated glycoproteins by plasma membranes of rat liver. J Biol Chem. 1971; 246:4825-4833.
Witten J and Ribbeck K. The particle in the spider’s web: transport through biological hydrogels. Nanoscale. 2017;9:8080-8095.
Dosio F, Arpicco S, Stella B, Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev. 2016; 97:204–236.
Wei X, Shao B, He Z. Cationic nanocarriers induce cell necrosis through impairment of Na+/K+-ATPase and cause subsequent inflammatory response. Cell Res. 2016; 25(2):237.
Zhang C, Gaona S, Ju Z, Huijuan S, Jinfeng N, Shengbin S, Pingsheng H, Yanming W, Weiwei W, Chen L, Deling K. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy. J Cont Rel. 2017; 256:170-181.
Eleonora M, Luca C, Cecilia R, Eliana L, Maria AC, Francesca B, Eleonora T, Valentina I. Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-dmannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. Int J Pharm. 2017; 528: (1-2):440-451.
Carneiro SP, Carvalho KV, Soares RD, Martin C, Andrade MHG, Duarte RS, Santos OH. Functionalized rifampicinloaded nanostructrured lipid carrier enhance macrophages uptake and antimycobacteril activity. Coll Surf B: Biointer. 2019; 175:306-313.
Tiwari S, Chaturvedi AP, Tripathi YB, Mishra B. Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres. AAPS. 2011; 12(3):900-908.
Beningo KA and Yu-Li W. Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. J Cell Sci. 2002; 15(115):849-56.
Sharma A, Vagashiya K, Verma RK. Inhalabe microspheres with hierarchial pore sixe for tuning the release of biotherapeutic in lungs. Microp Mesop Mat. 2016; 235:195- 203.
Nishimura S, Takami T, Murakami Y. Porous PLGA microparticle formed by ‘one-step’ emulsification for pulmonary drug delivery: the surface morphology and the aerodynamic properties. Coll and surf B: Bionter. 2017; 159:318-326.
Baldeli A and Vehring R. Analysis of cohesion forces between monodisperse microparticle with rough surface. Coll Surf. A : Phys Eng Asp. 2016; 506:179-189.
Contreras LG, Sung J, Ibrahim M, Elbert K, Edwards D, Hickey A. Pharmakokinetics of inhaled rifampicin porous particle for tuberculosis treatment: insight into rifampicin absorption from the lungs of guinea pigs. Mol Pharm. 2015; 12(8):2642-2650.
Chvatal A, Rita A, Petra P, Gabor K, Orsolya JL, Piroska S, Elias F and Nicolas T. Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. Int J Pharm. 2019; 559:68-75.
Paula GA, Benevides NM, Cunha AP, de Oliveira AV, Pinto AMB, Morais JPS, Azeredo HMC. Development and characterization of edible films from mixtures of κ-carrageenan, ι-carrageenan, and alginate. Food Hydrocoll. 2015; 47:140-145.
Ramaiah B, Nagaraja, SH, Kapanigowda, UG. High azithromycin concentration in lungs by way of bovine serum albumin microspheres as targeted drug delivery: lung targeting efficiency in albino mice. DARU J Pharm Sci. 2016; 24:14.
Viswnathan V, Mehta H, Pharande R, Bannalikar A, Gupta P, Gupta U, Mukne A. Mannosylated gelatin nanoparticles of licorice for use in tuberculosis: Formulation, in vitro evaluation, in vitro cell uptake, in vivo pharmacokinetics and in vivo anti-tubercular efficacy. J Drug Deliv Sci Tech. 2018; 45:225-263.
Li Z, Zheng H, Li X, Su J, Qin L, Sun Y, Guo C, Moritz B, Moehwald M, Chen L, Zhang Y, Mao S. Phospholipidmodified poly(-co-glycolide) microparticles for tunung the interaction with macrophages: in vitro and in vivo assessment. Eur J Pharm Biopharm. 2019; 143:70-79.
Hamilton R, Thakur SA, Holian A. Silica binding and toxicity in alveolar macrophages. Free Rad Biol Med. 2008; 44(7):1246-1258.
Sano H and Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol. 2005; 42:279-287.
Jones BG, Dickinson PA, Gumbleton M, Kellaway IW. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Int J Pharm. 2002; 236:65-79.
Ventura CA, Tommasini S, Crupi E, Giannone I, Cardile V, Musumeci T, Puglisi G. Chitosan microspheres for intrapulmonary administration of moxifloxacin: Interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm. 2008; 68(2):235-244.
Kolensyk I, Konovalova V, Burhan A. Alginate/κ- carrageenan microspheres and their application for protein drug controlled release. Chem Chem Tech. 2015; 9(4):485- 492.
Gaspar MC, Alberto AC, Pais-João JS, Julien B, Jean CO. Development of levofloxacin-loaded PLGA microspheres of suitable properties for sustained pulmonary release. Int J Pharm. 2019; 556:117-127.
Bitencourt C, da Silva LB, Pereira PA, Gelfuso G.M, Faccioli L.H. Microspheres prepared with different copolymers of poly(lactic-glycolic acid) (PLGA) or with chitosan cause distinct effects on macrophages. Coll Surf B Biointer. 2015; 136: 678-686.
Gizem RT, Burcu D, Müjde E, Asuman B. Design of ciprofloxacin-loaded nano-and microcomposite particles for dry powder inhaler formulations: preparation, in vitro characterisation, and antimicrobial efficacy. J Microencaps Micro Nano Carr. 2018; 35(6), 533-547.
West AP, Brodsky IE, Rahner C, Woo DK, ErdjumentBromage H, Tempst P. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011; 472:476-480.
Vaghasiya K, Eram A, Sharma A. Alginate Microspheres Elicit Innate M1-Inflammatory Response in Macrophages Leading to Bacillary Killing. AAPS. 2019; 20:241.
Elbi S, Nimal TR, Rajan VK, Baranwal G, Biswas R, Jayakumar R, Sathianarayanan S. Fucoidan coated ciprofloxacin loaded chitosannanoparticles for the treatment of intracellular and biofilm infections of Salmonella. Coll Surf. B: Biointer. 2017; 160:40-47.
Abdelghany SM, Alkhawaldah H, Al Khatib. Carageenanstabilised chitosan alginate nanoparticles loaded with ethionamide for the treatment of tuberculosis. J Drug Deliv Sci Tech. 2017; 39:442-449.
Mura S, Hillaireau H, Nicolas J, Kerdine-Römer S, Le DB, Deloménie, CN, Pallardy M, Tsapis N, Fattal E. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromol. 2011; 12:4136-
Bagre A, Narendra KL, Mohan LK. Therapeutic Management of Pulmonary Tuberculosis by Mannosylated Chitosan Ascorbate Microspheres: Preparation and Characterization. J Drug Deliv Ther. 2019; 9(3):13-25.
Gaspar MC, Sousa AP, Cardoso O, Murtinho D, Serra MS, FTewes, Olivier JC. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur J of Pharm and Biopharm. 2015; 96:65-75.
Oliveira PM, Matos BN, Pereira PAT, Gratieri T, Faccioli LH, Marcilio SS, Filho C, Gelfuso GM. Microparticles prepared with 50-190 kDa chitosan a carriers for pulmonary delivery of isoniazid. Carb Pol. 2017; 174:427-431.